Results 261 to 270 of about 939,495 (280)

RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape

Oncologist, 2023
Silvia Novello, Niels Reinmuth, Raffaele Califano   +2 more
exaly  

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer

Annals of Oncology, 2020
Sai-Hong Ignatius Ou, J F Gainor, L J Wirth   +2 more
exaly  

Diagnostics, therapeutics and RET inhibitor resistance for RET fusion–positive non-small cell lung cancers and future perspectives

Cancer Treatment Reviews, 2021
Qing Zhou
exaly  

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program

Therapeutic Advances in Medical Oncology, 2021
Stephen Clarke, Arschang Valipour, Massimo Di Maio   +2 more
exaly  

RET fusions in a small subset of advanced colorectal cancers at risk of being neglected

Annals of Oncology, 2018
Michele Prisciandaro, Chiara Gigliotti, Federica Di Nicolantonio   +2 more
exaly  

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

New England Journal of Medicine, 2020
Benjamin Besse, Kevin T Ebata, Justin F Gainor   +2 more
exaly  

KIF5B-RET fusions in Chinese patients with non–small cell lung cancer†‡

Cancer, 2013
Caicun Zhou, Chunxia Su, Weijing Cai
exaly  

Novel targets in non-small cell lung cancer: ROS1 and RET fusions.

Oncologist, 2013
Justin F Gainor
exaly  

Faculty Opinions recommendation of A RET::GRB2 fusion in pheochromocytoma defies the classic paradigm of RET oncogenic fusions.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature, 2022
openaire   +1 more source

ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: A comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features

Lung Cancer, 2014
Yuan Li, Lei Shen, Ting Ye
exaly